拉米夫定治疗慢性乙型肝炎及乙型肝炎病毒携带者的疗效评价

目的：观察拉米夫定对慢性乙型病毒性肝炎和病毒携带的疗效。方法：将92例病人分为治疗组50例，对照组42例，治疗组用拉米夫定100mg.d^-1。疗程52wk。治疗前后作肝功能。HBV－二对半HBV－DNA的测定。结果：治疗12wk时，治疗组与对照组ALT复常率的差异无的统计学意义（P＞0．05），但对于HBV－DNA阴转率，治疗组显高于对照组（P＜0．01）。治疗52wk时，治疗组ALT复常率和HBV－DNA阴转率分别为79．4％，74．0％，而对照组为46．9％和7．1％（P＜0．05），结论：拉米夫定能有效地抑制乙肝病毒的复制，是治疗慢性乙型肝炎的安全有效药物。

Clinical evaluation of lamivudine in treatment of patients with chronic hepatitis B and asymptomatic carriers

AIM: To study the curative effects of lamivudine in treatment of patients with chronic hepatitis B and asymptomatic carriers (AsC). METHODS: 92 cases with chronic hepatitis B and AsC were divided into treatment group (n=50) and control group (n=42). 50 cases in the treatment group received lamivudine 100 mg diary for 52 wk. Before and after the treatment, liver function, HbsAg, anti HBs, HbeAg, anti Hbe, anti HBc, and HBV DNA were tested. RESULTS: After 12 wk, ALT normalization rate had no difference in two groups ( 87.2 % vs 75.0 %, P> 0.05 ), and the negative transforming rate of HBV DNA in treatment group was much higher than that in control group ( 82.0 % vs 0, P< 0.01 ). After 52 wk, the ALT normalization rate and negative transforming rate of HBV DNA in treatment group were 79.4 % and 74.0 %, respectively, which were much higher than those 46.9 % and 7.1 % (P< 0.05 ) in control group. CONCLUSION: Lamivudine may effectively control the reproduction of hepatitis B virus and is an effective agent in treatment of chronic hepatitis B.